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Abstract
How are “interesting” research problems identified and made durable by
academic researchers, particularly in situations defined by multiple evalua-
tion principles? Building on two case studies of research groups working on
rare diseases in academic biomedicine, we explore how group leaders
arrange their groups to encompass research problems that latch onto
distinct evaluation principles by dividing and combining work into “basic-
oriented” and “clinical-oriented” spheres of inquiry. Following recent
developments in the sociology of (e)valuation comparing academics to
capitalist entrepreneurs in pursuit of varying kinds of worth, we argue that
the metaphor of the portfolio is helpful in analyzing how group leaders
manage these different research lines as “alternative investment options”
1Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe
Observatory Quarter, Oxford, United Kingdom
2Centre for Science and Technology Studies, Leiden University, Leiden, the Netherlands
Corresponding Author:
Alexander Rushforth, Nuffield Department of Primary Care Health Sciences, University of
Oxford, Radcliffe Observatory, Woodstock Road, Oxford OX2 6GG, United Kingdom.
Email: alexander.rushforth@phc.ox.ac.uk
Science, Technology, & Human Values
1-28





from which they were variously hoping to capitalize. We argue portfolio
development is a useful concept for exploring how group leaders fashion
“entrepreneurial” practices to manage and exploit tensions between mul-
tiple matrices of (e)valuation and conclude with suggestions for how this
vocabulary can further extend analysis of epistemic capitalism within science
and technology studies.
Keywords
academic disciplines and traditions, politics, power, governance, accounting
practices
Introduction
Classic studies of laboratories in science and technology studies (STS)
showed how in seeking to study “ripe” intellectual problems, researchers
would align what they considered “interesting” problems (based on their
interpretation of the research frontier) with a myriad of mundane factors,
which, together, would determine whether the research was deemed
“doable” or not (Fujimura 1987). In fields like biomedicine, Fujimura
showed how laboratory leaders put in place conditions for the construction
of doable problems through “articulating alignment” between experimental,
laboratory, and social world levels of work organization. Hackett (2005)
later added to this perspective, arguing group leaders—henceforth principal
investigators—pay extremely close strategic attention to opening “spheres
of inquiry,” namely, research problems that they not only deemed “doable”
but would likely also help the laboratory to establish an independent and
durable identity within a field(s) of research (Hackett 2005, 787). Continu-
ing this tradition, much contemporary research on the organization of sci-
entific research pays close attention to how research governance is shaping
the research process. Although cautious to embrace wholeheartedly the idea
of epochal transitions toward “mode 2,” “new public management,” or
“neoliberal science,” a growing number of researchers in STS have become
increasingly interested and concerned about how “technologies of govern-
ment” like performance indicators, audits, and standards (Miller and Rose
2008) are coming to reshape academic practices and selves (Felt 2009;
Stöckelová 2012; Sigl 2016; Hammarfelt, de Rijcke, and Rushforth 2016;
Hammarfelt and Rushforth 2017; Kaltenbrunner 2017; Franssen et al.
2018).
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At the same time, emerging research on the sociology of (e)valuation has
sought to examine the construction and effects of practices for evaluating
performance within research and other domains of public policy (Lamont
2012; de Rijcke et al. 2016). Resisting singular notions of “excellence” so
often inscribed in technologies for monitoring and evaluating performance,
much of the emerging research on (e)valuation posits that as performance is
in practice being evaluated through numerous diffuse technologies and
standards, academic research is becoming increasingly accountable to mul-
tiple—sometimes complementary, sometimes conflicting—evaluative
infrastructures and regimes of worth (Stark 2009; Helgesson and Muniesa
2013). Drawing on STS and sociological work on (e)valuation, we seek to
consider what this multiplicity means for the long-standing concern of
studies of scientific work in laboratories, namely, how do research group
leaders strategically construct their inquiries?
To address this puzzle, with others, we return to early insights in STS
that compared researchers to capitalists. This analytical connection to cap-
ital and capitalism can be traced back to Bourdieu (1975) and, subsequently,
Latour and Woolgar’s (1986) credibility cycle and Etzkowitz’s (2003)
account of research groups as “quasi-firms.” Prompted partly by the grow-
ing specter of (e)valuation, Hackett (1990, 2014), Fochler (2016), and
Muniesa et al. (2017) have argued that STS has underutilized the analytic
potential of capitalism as a metaphor and model for understanding aca-
demic research in recent times. One of the motivations for revisiting earlier
analogies is that the rise in performance has brought about the sense that
individual researchers are being rendered increasingly self-actualizing (and
self-responsible) “entrepreneurial” figures needing to become adept at
accumulating worth from their research within “marketplaces of ideas”
(Mirowski 2011). In short, the individual researcher is becoming more and
more like a capitalist. To investigate the implications for contemporary
academic research practices, Fochler (2016) introduces the term epistemic
capitalism, broadly conceived as “the accumulation of capital, as worth
made durable, through the act of doing research” (p. 924). Fochler goes
on to explain that the changing governance of academic research means that
faculty and junior researchers are not simply “entrepreneurs” in a more
restricted sense of commercializing their research but more broadly that
they have become “entrepreneurial managers of their own careers, publi-
cations, and grant portfolios” (Fochler 2016, 924).
Importantly, the notion of capitalism here is not limited simply to
accumulation of monetary capital but also to generating and accumulating
other forms of worth that are durable enough to deploy as capital. In this
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scheme, while various kinds of worth may be cited by researchers as
important and motivating, not all forms can be accumulated and rein-
vested in subsequent cycles of credit. For instance, producing research
that goes “against the grain” or is ambitious may embody forms of
epistemic worth with which researchers readily identify, yet in some
institutional and disciplinary settings this work may not be capitalized
upon by the researchers unless it has also appeared in a journal with, say,
a high journal impact factor (JIF) score or goes onto attract a consider-
able number of citations (Rushforth and de Rijcke 2015). Focusing on
capitalistic dynamics in the research process thus entails drawing atten-
tion to how multiplicitous forms of worth and the possibilities for accu-
mulating capital from them shape the organization of academic research.
This means approaching “capitalistic” or entrepreneurial strategies of
accumulating worth not as heroic individual traits, but primarily as con-
stituted through organizational routines and practices, which may be more
available to some than others (Stark 2009). Recent sociological theory on
(e)valuation also holds that situations defined by conflicting forms of
worth need not necessarily be considered debilitating, because, in fact,
like other forms of creative inquiry, research may even profit from “the
ability to keep multiple principles of evaluation “in play” and to benefit
from that productive friction” (Stark 2009, 6). In our view, a broadened
account of epistemic capitalism raises important questions for the study
of academic research in STS: How is academic work organized to keep
different forms of worth in play? How are different forms of worth
undergirded by specific organizational routines and infrastructures? How
do assumptions about the relative durability of different evaluation prac-
tices guide the selection and combination of epistemic spheres of inquiry?
In this paper, we build on these emerging issues by describing strategies
employed by principal investigators of two biomedical research groups in
an academic medical center in the Netherlands. We argue that the portfolio
provides a useful concept for describing how these principal investigators
strategically managed their “spheres of inquiry” (Hackett 2005) so as to
satisfy a dominant regime of worth, while also keeping alternative forms of
worth in play should they become more viable in future. Our account of
portfolio strategies is elaborated on principal investigators’ strategies for
oscillating between two particular spheres of inquiry that appear ubiquitous
in contemporary biomedicine: broader, fundamental (“basic”) research ver-
sus narrower, applied (“clinical”) research.
The term portfolio is often used in the world of finance to refer to the
complete investments of a company, in art to refer both to a flat folder in
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which drawings are kept and the artist’s range of works. While this has been
used as a metaphor to describe the range of projects invested in by research
funders (Wallace and Rafols 2015), to our knowledge, it has not yet been
the explicit focus of STS research on academic knowledge production.
Similar to these vernaculars, we use portfolios to refer to the range of
inquiries being worked on by researchers and research groups at a given
moment. Informed by earlier work on laboratories in STS, we consider
research portfolio construction efforts to be made possible and limited by
a laboratory’s “research technology ensemble,” that is, configurations of
materials, techniques, instruments, and ideas and enabling theories drawn
upon in producing new research (Hackett et al. 2004, 748). Technology
ensembles tend to build up and evolve in ad hoc fashion as local adaptations
of international “research systems”: sets of epistemic practices, technolo-
gies, and standards used within international fields of research to make
particular epistemic objects knowable (Hackett et al. 2016). Rheinberger
(1997) describes such ensembles (what he calls “experimental systems”) as
important in helping to create stability in the practices and identities of
research laboratories (“reproduction”) amid constant turnover in
“personnel, results, and environment” (cited in Hackett 2005, 794). He
contends that technological ensembles are not only “machines” for extract-
ing or testing particular forms of information but also underpin open-ended
inquiries into phenomena (“machines to make a future”; Rheinberger 1997).
However, as well as making particular spheres of inquiry possible and
durable, over time research technology ensembles generate path dependen-
cies and inertia for groups, narrowing how their work is identified among
international colleagues and competitors (“signature”; Jacob 1989) and
constraining the research problems members of the group are likely to
consider doable (Fujimura 1987). Given that fates of principal investigators
and personnel are to varying degrees tied into the affordances and con-
straints of their technological ensembles, it is not surprising that, much of
the time, the thoughts and energies of principal investigators center on
negotiating “essential tensions” of reproduction and replenishment (Hackett
2005; Foster, Rzhetsky, and Evans 2015). Building on these perspectives,
the concept of “portfolios” offers a timely way of sensitizing how principle
investigators develop entrepreneurial strategies for consolidating and
refreshing spheres of inquiry against a multiplicity of worth regimes in
contemporary biomedical research.
This paper is organized as follows. In the following section, we argue
that the different kinds of worth regimes circulating in contemporary bio-
medical research resemble what Stark (2009) labels “heterarchy.” Accounts
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of worth in biomedicine have often swung between notions of basic and
“applied” research, which, while long-standing in the history of the field,
have also found renewed expression and urgency in recent debates about the
performance and governance of biomedical sciences in the Netherlands and
beyond. We then give an overview of the fieldwork and methods used to
study our two cases, before presenting the main findings. In the first section
for each case, we discuss how different kinds of research questions that
were posed within the groups related to basic or applied clinical forms of
epistemic worth. In the second section of each case, we then describe how
portfolio arrangements enabled the group leaders to capitalize on research
lines from these two spheres of inquiry by drawing on two regimes of worth:
excellence and “patient relevance”. We end by discussing the significance
of the findings in relation to recent STS interest in academic (e)valuation
practices and epistemic capitalism.
Basic and Applied Spheres of Inquiry in Biomedicine
As with previous STS works on basic research, we do not hold there to be
any essential distinction between basic and applied clinical knowledge per
se, as such terms are well known to serve rhetorical functions as political
symbols in various science policy and research communities (Pielke 2012;
see also Calvert 2006). However, it would be analytically shortsighted to
consider these categories as purely rhetorical or illusory (Hoffman 2015).
Historical accounts of biomedicine have shown convincingly how, since the
second half of the Twentieth Century, distinctions between basic and clin-
ical research have come to be reified and inscribed within institutions of
academic biomedicine and clinical practice (Löwy 1996; Keating and Cam-
brosio 2003). Taking inspiration from Hoffman’s (2015) recent account of
how multiple realities of basic and applied research were enacted in the
context of an artificial intelligence research laboratory, our approach is to
describe how notions like basic and clinical research (and forms of worth
associated with them) fragment and multiply as our informants related to
different research problems in the course of their work. To do so, we draw on
and develop the argument that basic research and clinical research problems
relate to separate yet interacting “regimes of worth”: what our informants
categorized as excellence and patient relevance, respectively. Regimes of
worth are evaluative principles and associated forms of valuation that become
stabilized in institutional settings to the point where they constitute an obli-
gatory frame that individuals and groups accommodate in their research
(Fochler, Felt, and Müller 2016). For Fochler (2016), forms of worth become
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regimes of worth when they are underpinned by durable forms of capital.
Whereas some forms of inquiry might matter to researchers, when these do
not interlock with established regimes of worth they risk being displaced or
downgraded by research that does appeal to these standardized and powerful
practices of capital accumulation.
Biomedicine as Heterarchical Work Organization
Stark (2009) introduced the notion of heterarchy to conceptualize organiza-
tional settings in which multiple regimes of worth are maintained and
deployed by entrepreneurs. Indeed, it is the ability to mobilize and exploit
ambiguities and tensions between different worth regimes that defines
entrepreneurial activity. Contemporary biomedical research provides a rich
and elucidating site in which to study heterarchical work forms and epistemic
capitalism, given ongoing concerted efforts to shake up what is considered a
dominant regime of worth and make the field altogether more heterarchical.
As an institutional context that is subject to a host of different demands often
linked to the high levels of funding and expectations and accountability
invested by governments and other actors, there are a number of distinct
ways in which biomedical researchers demonstrate worth. Arguably, the
dominant regime—excellence—is often associated with the rise in biblio-
metric performance indicators such as the JIF and other citation-based indi-
cators. These measurements have come to play an important constitutive role
in shaping reputational dynamics in biomedical research, not only by virtue
of their use by “external” actors governing the allocation of funding and
career opportunities (Hessels, Van Lente, and Smits 2009) but also by the
propensity of researchers themselves to utilize and internalize the logics of
the indicators (Rushforth and de Rijcke 2015; Müller and de Rijcke 2017).1
Although standardized metrics of excellence have become an increas-
ingly stabilized and obligatory regime of worth in recent times (Fochler
et al. 2016), there have also been growing regional and international back-
lashes. Varied sources and movements have criticized standardized excel-
lence regimes in biomedicine for being at odds with patient-focused ideals
upon which the vast expenditure on biomedical research is usually man-
dated (Alberts et al. 2014; Benedictus, Miedema, and Ferguson 2016;
Macleod et al. 2014). Critiques of the JIF and bibliometric performance
indicators more widely often tap into long-standing concerns that invest-
ments in fundamental biomedical research are not being capitalized upon
efficiently or effectively enough in the form of tangible new health tech-
nologies, medicines, services, or outcomes. In recent times, “translational
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research” has become an increasing preoccupation for national and regional
health research policies in the form of initiatives purporting to bridge
“gaps” in the movement of knowledge discoveries from “bench-to-bedside”
(Woolf 2008; Rushforth and de Rijcke 2017). In spite of all these policy
efforts, one of the major hurdles said to be thwarting such reforms is the
persistence of the excellence worth regime that is focused on “high impact
factor” journals, around which career structures, funding, and individual
reputations still tend to interlock (Ioannidis 2017).
Against this backdrop, the board of the academic medical center in which
our cases were embedded was increasingly advertising “patient-relevant
research” as a priority even for more basic biomedical research groups and
was undertaking new initiatives to provide a “protected space” (Whitley
2014) for forms of work considered important but missing out within the
prevailing excellence regime. Building on a national movement, Science in
Transition (http://scienceintransition.nl/english), the senior management of
the medical center argued publicly that biomedical scientists—including
those in their own institution—have become “captured” by artificial metrics
(impact factors, citations, individual grants, institutional rankings), which
have diverted attention and priorities away from the “true vocation” of bio-
medical research, namely, to improve the health of patients and populations.
Efforts to “recapture” and nurture in-house the “lost” priorities of patient
relevance included introducing new evaluation procedures and promotion
criteria for staff, albeit at the time of the fieldwork, this was not at a scale or
level of development at which the groups we studied could yet capitalize. As
patient relevance was underscored only by an embryonic and rather promis-
sory set of evaluative practices at the time of fieldwork, we have termed this a
“prospective regime of worth” in our analysis. In some institutional domains,
a stable patient-relevant regime may already dominate and offer forms of
worth on which researchers can readily capitalize. Yet for these biomedical
research groups in this academic medical center, the notion that this prospec-
tive regime could erode or even displace the excellence regime was a new
reality for “shop floor” researchers.
Empirical Focus and Method
This paper presents material developed through a larger research project
about efforts to build capacity for research on rare (or “orphan”) diseases in
Europe. The European Union defines rare diseases as conditions that afflict
less than 1 in 2,000 of the general population (Orphanet n.d.). Whereas there
is a considerable body of literature on the role of patients and patient
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organizations in shaping research and innovation policy on rare diseases
(Rabeharisoa, Moreira, and Akrich 2014), in the lab-oriented research
groups, we studied patients were rather remote and present only in the form
of distant funders or providers of data for experiments. Instead, rare diseases
served mostly as models on which to base contributions to the fields of
cellular immunology and human genetics, respectively.
The empirical materials presented were drawn from ethnographic field-
work carried out by the first author in 2016-2017. Over a period of six
weeks per case, he participated as an observer in weekly meetings typically
attended by all lab members, one-to-one research meetings, lectures and
seminars, Skype and phone meetings with collaborators, and laboratory
work. He also met and held conversations with members of the group
separately as well as joining them for lunch on a number of occasions. In
the genetics case, he was able to shadow the principal investigator for
sustained periods by being located in his office. Semistructured interviews
were conducted with members of the groups, close collaborators, and
departmental colleagues, cutting across a range of career stages, from full,
associate, and assistant professors to clinical fellows, postdoctoral research-
ers, and PhD students (human genetics interviews ¼ 11, immunology inter-
views ¼ 9). The first author received forwarded e-mails, funding
applications, Curricula Vitae (CVs), and departmental vision documents
by various informants and accessed publications of principle investigators
via PubMed and browsed their institutional webpages.
For each case, our analysis will look first at how members of the two
groups defined “interesting” fundamental research problems on rare dis-
eases. This will reveal how notions of what the researchers and their inter-
national community find ripe become entangled with other forms of “worth
made durable”: “calculative infrastructures” (Kurunmäki and Miller 2013)
of citations and JIFs. The second section within each case then addresses
how groups were in turn configured with a view to rendering interesting
problems “durable” (Hackett 2005). This will shed light on the importance
of the portfolio as a concept for describing how principal investigators
strategically combine and align inquiries toward multiple worth regimes.
Immunologists
Making Rare Diseases Interesting Research Problems
How were the lines of inquiry pursued within the immunological research
group related to different regimes of worth? In analyzing cell activity within
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blood and serum samples, the broad aim of the immunology group’s work
was to open insights into the functioning of the immune system in the whole
human body. The group specialized in mechanisms of immune regulation,
often, but not always, in the context of childhood autoimmune diseases.
Within the international immunology field, the scientific name (or
“signature”) of the principal investigator and the group was most strongly
associated with the role of T cells in autoimmune regulation. Within the
parameters of project funding calls, immunological questions were
answered by taking a single disease as a model for analyzing mechanisms
active in inflammation processes. As they were primarily interested in more
theoretical puzzles, in principle taking common diseases or rare diseases as
a model would not necessarily alter the kind of research questions they
could pose:
Interviewer: I wondered, the fact that rare disease 1 is a rare disease, does
this change the research process at all?
Postdoc: Possibly, well of course, it does but it depends on what you
look at. In terms of questions, no not necessarily, I mean the
research questions for rare disease 1 are probably the same as
for RA [rheumatoid arthritis—a common disease] or for . . . I
mean at least for me, I’m interested in what the role of certain
cells is in diseases and the questions I posed here [on rare
disease 1] I could also pose in a different disease. (Postdoc 1
interview)
The value of these rare diseases (and their subtypes) as interesting models
for exploring broad, general questions about immunology was repeated
throughout the fieldwork:
What I also believe is that some of these [rare] diseases are very interesting
also intellectually so you can have a huge impact because there is a certain
mechanism or something that can help in the end a lot of people and ‘a lot of
science’. (Principle Investigator interview)
Two common ways of legitimating mechanisms-oriented research on a
rare disease are present in this quotation: contributing to a more general and
abstract good (helping “in the end a lot of people”) and in terms of gen-
erating knowledge with a comparatively broad appeal to a lot of science.
The breadth of appeal for a lot of science was a feature that aligned with and
reinforced the regime of worth centered on JIFs and attracting larger num-
bers citations. The “cite-ability” of more conceptual contributions is
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captured in the following statement recorded during an interview exchange
about why the Dutch national funding agency should support basic science
with rare diseases:
The thing is if you stimulate the science for these rare diseases, you will get
good papers that also will be cited a lot because there is a lot to discover and
also that can be translated to other diseases as well. (PI interview)
As someone trained in basic immunology research, the principal inves-
tigator was embedded in an epistemic domain where impact factors of
journals in which one publishes had become a de facto standard for measur-
ing quality. Her CV and application for an individual grant both proudly
displayed the “median impact factor score” of her outputs as a senior author
(i.e., on papers where she is listed as last author, representing independence
as a lab leader) as well as her “5-year H-index” score (which covered the
period in which she had become the sole principal investigator of her lab).
Informants in the group were able to explain readily what constituted recog-
nized ways of “making a splash” with their projects in what they considered
high impact factor immunology journals. A typical way of enrolling rare
diseases as part of a high-scoring paper in an immunology journal is
described in the following quotation:
Interviewer: One of the things I was thinking about was publishing. So if
you’re expected to publish in very high impact factor jour-
nals, are rare diseases a risky thing to take on?
PhD: Yes. I think there what we’re trying also in the lab is to use cool
techniques, new techniques, on these patient samples. So then,
in the end, your paper will become very interesting for a broad
public as well, since you’re using cool techniques or investigat-
ing basic immunological concepts, with the disease as a model
system, but not only focusing on that disease. So it’s more like
developing, or investigating, new basic concepts in immunol-
ogy that might apply to many other diseases, or even to a healthy
human and doing that using new techniques, cool techniques,
that have not been used a lot before. Then in the end, your paper
is interesting because other groups can use these same tech-
niques, or can somehow conceptually also use the basic immu-
nological findings that you have. (PhD 1 interview)
Here interesting papers are tightly coupled with having generalizable
findings with a broad appeal to an international immunology audience.
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“Bigger” contributions were also said to derive from working on the rela-
tively well-described and homogenous patient groups that characterized
the rare childhood disorders they would use for modeling immunological
mechanisms. This meant published findings on mechanisms in these well-
defined conditions could have the potential to be extrapolated to more
complex and common muscle or chronic rheumatic diseases where the
same mechanisms were also known to be important (Clinician Interview).
Their findings would thus likely attract more citations when their rele-
vance could be extrapolated beyond the given rare diseases and applied to
complex disorders.
Two contrasting research lines are particularly illustrative of how the
immunology group related “interesting problems” to the excellence regime.
Both were based on the role of T cells in immune regulation and repair, with
one focused on variations of a form of juvenile arthritis that is classified as a
rare disease but has a steady supply of patient samples obtained by clinical
colleagues in the children’s clinic (rare disease 1). Another more up-and-
coming line was set up on an ultrarare form of juvenile arthritis (rare disease
2), with fewer patients and samples than rare disease 1. At that moment in
time, the rare disease 1 research line was operating at such a scale that it was
considered much more likely to deliver broad, high-impact outputs than the
newer research line on rare disease 2. Thus, for rare disease 1, journals within
their main disciplinary specialty (immunology) with the highest impact fac-
tors were coveted as a source of reputation, with the JIF largely thought to
signal the novelty and generalizability of research in the journals.
The rare disease 2 research line started life when the principal investi-
gator obtained PhD project funds from a Dutch research charity and hired a
medical doctor in training (who had planned to return to training as a
specialist once the PhD was complete). The project involved close colla-
boration with a couple of clinicians in the Children’s Hospital, with the aim
of testing a subclinical biomarker within a clinical population. This kind of
work was what informants considered “applied clinical research,” that is,
testing whether something that was discovered in a lab works or not in a
clinical setting. At the time of fieldwork, the rare disease 2 research line was
not so amenable to producing high-JIF scoring conceptual studies, however,
partly because the disease was ultrarare, meaning patient samples were
difficult to access and the disease was less studied in the immunology
community overall. As such, this project was likely to have “lower impact”
compared to conceptual immunological work, as it would likely reach
smaller audiences in fields like rheumatology where readers of journals
would be primarily interested in the rare disease itself. According to
12 Science, Technology, & Human Values XX(X)
informants, in the short term, only patient groups were interested in funding
this research, which, stereotypically at least, tended to value funding
shorter-term clinical research over more abstract general questions. Over
time, the principal investigator was hopeful the lab might be able to build a
large enough research infrastructure to be able to produce conceptual papers
on rare disease 2 that would be eligible for high-JIF immunology journals.
However, in the short term, the rare disease 2 PhD project had shoehorned
basic research questions into clinically oriented funding calls. The more
basic research questions conducted within the rare disease 2 line could thus
be conceptualized as standing in promissory relation to the excellence
regime, while the applied clinical questions were profitable in the patient
relevance regime of worth. How the immunology group was organized in
order to exploit accumulation of capital through both excellence and
patient-relevant regimes of worth is the topic to which we now turn in
further detail.
Accumulating Different Forms of Capital through a Portfolio
Two research lines, separable in terms of disease focus (rare disease 1 and
rare disease 2), had emerged and become stabilized within the immunology
group. At the time of fieldwork, the two research lines represented two
types of epistemic inquiry, both of which tend to persist in academic bio-
medicine: more general, basic research and more applied, clinical research
problem-solving. The two research lines also drew on two distinct regimes
of worth. But how did these two regimes of worth interact, and how was the
discord exploited (cf. Stark 2009) within the group? While the move of
setting up a lower-impact line on rare disease 2 appears to run counter to the
excellence regime, in this section, we describe how, in diversifying the
groups’ research focus, the principal investigator in fact sought to capitalize
from combining basic and clinical research.
rare disease 2 was piloted as part of a doable clinical research project that
could be performed by a clinical researcher in the space of four years. The
project drew on some immunological techniques similar to other basic
research projects on rare disease 1 running in the lab. Therefore, they hoped
that a rare disease 2 project might generate some findings that could be of
interest to higher-JIF immunology journals, if not in this PhD project then in
subsequent follow-up projects. In other words, promising results might lead
the principal investigator to try to scale up rare disease 2 into a larger research
line, which could appeal to the excellence regime of worth. But if not, it was a
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low-risk option that would be justifiable in terms of the local patient rele-
vance regime of the academic medical center.
As well as delivering findings that, in the short term at least, would latch
onto the emerging patient relevance regime, it was hoped that introducing
rare disease 2 into the lab would also bolster the vitality of the rare disease 1
research line in yielding results that could appeal to high impact factor
immunology journals. The principal investigator reasoned that adding rare
disease 2 would generate inspiration and exchange of ideas between proj-
ects and individuals in the lab who worked on different disease models but
were united epistemically by a focus on similar immunological
mechanisms.
Interviewer: You work with a portfolio of diseases, does there need to be
some flexibility in terms of looking at more than one disease
and being a specialist on more than one disease in the group?
PI: Yes. That’s also why I try to have meetings where they [mem-
bers of the group] are all together although they may work on
very different diseases but that they will know from each
other because they also learn . . . . So I try to keep it pretty
general so they also learn to think not only in the [one] dis-
ease . . . they [group members] have to think in a way that they
can not only answer questions on one thing. (PI interview)
A professor who was formerly principal investigator of the immunology
group similarly described how answering broad questions relies on diverse
conversations and interactions with different kinds of research and clinical
communities. One potentially inhibiting factor for a self-identifying basic
researcher focusing solely on one rare disease would be a relative lack of
inspiration owing to interacting only with members of a single, diminished
research community:
. . . there are no more than four or five centers in the world who work on this
[rare disease 1] . . . . If you would stay in this field, you would be—it’s like the
one-eyed being, the King of the Blind, it’s like a very small community. Basic
research is done, I think, in four centers in the world. So if you are the only
ones, so you only get your input from three other centers, which is also why
it’s very important to broaden your scope to other diseases, other fields,
because otherwise there is nothing of innovation. (Professor interview)
Having a portfolio of inquiries on different diseases utilizing an in-house
technology ensemble therefore served to boost the likelihood that one of the
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diseases—rare disease 1—would produce novel, innovative outcomes out
of which papers would emerge high-JIF immunology journals. Thus,
although setting up projects on a different disease with a more clinical focus
would not (yet) in itself satisfy the excellence regime centered on the JIF,
this move helped to render rare disease 1 a more durable research line out of
which interesting basic immunological ideas and “high impact factor” con-
tributions could emerge in the shorter term. As such, the decision that might
have appeared to be a counterintuitive move that would eat up scarce
resources to satisfy the excellence regime of worth was, in fact, explained
as providing a sustainable means of continuing basic research within the
academic medical center—while also capitalizing on the additional regime
of worth associated with patient relevance.
This entrepreneurial ability to oscillate between spheres of inquiry that
draw on different regimes of worth is one way in which basic research
inquiries are made sustainable in a context in which “social accountability”
and patient relevance is being promoted as a prospective regime that could
challenge the excellence regime of worth.
Human Genetics
Making Rare Diseases Interesting Fundamental
and Clinical Problems
The human genetics group worked on the genetics of rare diseases, many of
which were metabolic disorders. Since many rare genetic conditions are
caused by a single-gene mutation (compared with more common, complex,
multifactorial diseases), the group brought together two core technologies
to study this area. First, they used genetic tests and sequencing technologies
to identify the causal mutations in many monogenic disorders. Since the
mid-2000s, rapid changes in sequencing techniques—especially Next Gen-
eration Sequencing (NGS) techniques such as whole-genome sequencing
and whole-exome sequencing—have played an important promissory role
in genetic science and medicine (Timmermans and Shostak 2016). In the
context of the research frontier of the human genetics field where this group
worked, NGS developments had led to a “gold rush” in efforts by research-
ers to discover and link newly identifiable genes to disease phenotypes in
patients. Second, the group coupled NGS with the so-called functional
work, performing gene knockouts (using zebra fish) to model developmen-
tal problems in identified monogenic rare disorders.
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The packaging of sequencing and functional techniques had hitherto
been interpreted as a research technology ensemble that could, in some
instances, yield publications in what were considered high impact factor
genetics journals. Aside from the general promise of combining these
techniques, there were certain other qualities that might render manu-
scripts emerging from this pipeline eligible for journals with higher
impact factor scores. What several informants considered to be the most
important article the principal investigator had produced as senior author
was explained as a “good fit” for a high-impact genetics journal because it
made a convincing case that the gene they identified belonged to a distinct
class of genes and was therefore particularly novel and interesting for the
international scientific community. As researchers who are clearly iden-
tified with values like novelty and general applicability (and who saw
these reflected in JIF scores in their field), in one sense the practice of
sorting journals from high to low JIF scores was seen as relatively unpro-
blematic and useful.
Projects might also yield outputs in prestigious journals in genetics by
making a convincing argument that the gene they had identified could be a
screening candidate for DNA diagnostic tests. In such instances, their fun-
damental approach would yield what they termed “instantly applicable”
clinical implications, as (imagined) clinicians adopting their findings could
improve the diagnostic screening and disease management for patients.
Informants were able to align certain projects with the two regimes of
worth, for instance, by citing examples of results that were published in
high-impact journals and that could be mobilized to persuade funders,
managers, and clinicians of the patient relevance of their work. What is
interesting in the above examples of “high-impact” outputs associated with
JIFs is that they do not occlude a priori other pertinent values in biomedical
research, such as patient relevance or clinical translation, which is often
implied in more outspoken “folk theories” on the influence of citations and
the JIF in biomedicine (Rushforth and de Rijcke 2015). While on occasion
there could be alignments between these regimes, tensions still tended to
occur, more often than not. Informants would acknowledge, for instance,
that values associated with patient relevance could be eclipsed by evalua-
tion practices synonymous with excellence regimes. The following state-
ment from the principal investigator explains why he believes a recent
manuscript they submitted to one of the top three human genetics journals
in terms of JIF was sent out for review rather than desk rejected by the
journal’s editor:
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The reason I think that this story is now in the review [process] while other
stories, which are scientifically as sound as this one are not [in review], is that
this is the first developmental syndrome caused by a mutation in the [names
type of protein]. While other stories might have a bigger impact on patients,
because there are slightly more patients [from the disease cohort], but it’s a
less exciting gene, so to say. (PI interview)
Clearly, then, research problems and techniques may not appeal to the
values of high-impact genetics journals (novelty, sexiness, general applic-
ability), yet they can provide important answers to problems that would be
highly relevant for rare disease patients, families, or clinicians.
The manuscript under review at the high-impact genetics journal was
contrasted with another project running concurrently, which would not
yield forms of novelty that high-impact genetics journals would value, and
yet would be highly relevant for the patient group on which the project was
modeled:
The [higher impact] project is a new link between a gene and a disease, but
the disease is more rare than [the lower-impact project’s] syndrome. But the
novelty is really playing a big role there, and the type of gene—it’s novel to a
class of genes even. [The syndrome in the lower-impact project] is genetically
[known] . . . we already published it in 2012, and now we’re looking to further
understanding this orphan [rare] disease. So it will have a lower potential of
getting citations, because there are less people working on it and less people
interested in it. (PI interview)
Work that was considered dull but important for patients was therefore
seen as somewhat in tension with priorities to produce exciting science,
which can be capitalized upon by publishing work in higher impact factor
titles and accruing larger numbers of citations.
In the following section, we describe how lower-impact “patient-
relevant” projects were configured alongside high-impact projects in the
organization of the human genetics group.
Accumulating Different Forms of Worth through a Portfolio
Having identified how lines of inquiry across the group were related to
different regimes of worth, we will now focus on how a “portfolio” of
projects focused on the local research technology ensemble was imagined
to exploit said regimes of worth. In the five years since the group was
established, connecting NGS techniques with functional studies of model
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organisms to study rare genetic diseases had proved quite profitable in
accumulating capital associated with publishing in high-impact human
genetics journals, with grants coming in and the group and external colla-
borations growing.
This profitable practice of combining sequencing and functional
approaches had been routinized in the form of a common “pipeline” of
experimental procedures, on which most of the different rare disease proj-
ects could be based. This relatively stable production line had enabled
flexibility and economies of scale around which all kinds of externally
funded projects on rare genetic diseases could be configured.
While this had hitherto supported projects that had led to novel outputs in
high-impact genetics journals, around the time of fieldwork, the PI had also
just recently begun to initiate lower-impact projects around this configura-
tion based on more “applied” disease-oriented research problems and tech-
niques. A functional testing project had been recently set up that
experimented with different therapeutic interventions in zebra fish in order
to describe their effects on development. This did not include NGS com-
ponents and as such the novelty of the findings and techniques was seen as
insufficient to interest the higher-impact genetics journals. The need to
generate “investment alternatives” through a portfolio of more basic and
more disease-focused clinical projects was related to a changing trend
beginning to emerge in the human genetics field. One important consider-
ation was that the rate of discovery of genetic causes of monogenic rare
diseases, which had proliferated in light of international adoption of NGS
techniques, was beginning to dry up. A well-cited review article in Nature
Reviews Genetics makes the following (bold) claim to this effect:
Work over the past 25 years has resulted in the identification of genes
responsible for *50% of the estimated 7,000 rare monogenic diseases, and
it is predicted that most of the remaining disease-causing genes will be
identified by the year 2020, and probably sooner. (Boycott et al. 2013, 681)
The anticipated contracting of opportunities to identify novel genetic
causes was, according to informants, already posing threats to the durabil-
ity of their current experimental pipeline. The “drying up” of interest was
not simply something that was anticipated to occur in the near future but
was already becoming apparent, as editors of the high-impact genetics
journals were beginning to desk-reject studies of this kind that had pre-
viously, in their estimations, stood good chances of being published.
Therefore, as their approach was no longer likely to yield high-impact
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papers, a “plan b” needed to be considered. The following field note
describes a conversation held just before a lecture given by the first author
to the human genetics group:
The principal investigator states that once the monogenic disease genes dry
up, he will have to drop down the impact factor of the journals in which he
can publish. He does not have the expertise or the credibility to move into the
really fundamental biology of zebra fish which the life sciences group [with
whom they collaborated] focus upon . . . . He says he will go more toward
functional testing in future, where different treatments are given to zebra fish,
and their development is then subsequently monitored. They can question for
example “does a given treatment reduce the swelling of vessels?” This in turn
may allow them to suggest treatments as potential therapeutic options for
human patients with the rare diseases. (Field note feedback meeting)
Whereas the identification of a novel disease-causing gene or gene type
(“discovery studies”) can attract a wide-ranging audience in human genet-
ics, testing potential treatment options through gene knockout studies is
seen as simply an application of existing techniques. One such functional
project within the group at the time of fieldwork was pointed to by the
principal investigator as a model for what many more future research proj-
ects would come to look like. This project was considered lower risk and
therefore likely to have lower impact in terms of citations; yet it also
symbolized the start of a shift away from prioritizing the excellence regime
associated with NGS and toward projects that were expected to latch onto
an alternative regime of worth on the horizon that would be associated with
patient-relevant research. Moving from publications in higher-JIF-scoring
genetics journals toward lower-JIF-scoring medical journals could be legiti-
mated, it was hoped, by appealing to the fact that the senior managers in the
academic medical center in which they were located were advertising con-
spicuously a shift in priorities toward patient-relevant research. The follow-
ing field note describes a follow-up question posed by the first author about
the institutional recognition of this alternative accumulation dynamic:
I ask whether the medical center and his [the principal investigator’s] depart-
ment would accept him dropping down the impact factor scale in which he
can publish. He states that the future work will have a lot of potential for
identifying new treatment options. Therefore if the medical center is serious
about making patient-relevant research a priority like it says it is, then it
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should support him, putting its money where its mouth is. (Field note feed-
back meeting)
During the meeting that followed with the group, the PI made the likely
legitimacy of the new forms of investment clear:
For me it is a factor that I don’t need an impact [factor score] of this and this
every year. As long as I can explain why I have lower-impact publications,
then it is fine. (Field note feedback meeting)
The portfolio can thus be seen as a metaphor and model that speaks to the
principal investigator’s felt need to organize projects in a way that enables a
durable research line situated at the intersection of two regimes of worth.
While this portfolio concept is very much consistent with the image of
principal investigators as entrepreneurs seeking to capitalize opportunisti-
cally upon different regimes of worth, the ability to shift via this particular
portfolio arrangement toward an alternative regime (patient relevance) is
dependent upon associated values somehow being made durable enough
within his institution to become capitalizable. Thus, the portfolio arrange-
ment described, while not guaranteeing survival, does enable the principal
investigator (a) to open up toward the rather diffuse, ephemeral values
associated with patient-relevant research and (b) to capitalize on values
associated with doing patient-relevant research if it fulfills the promise of
becoming a durable regime within his institution. In short, shifting regimes
only works in an institutional context that is prepared to recognize and
uphold heterarchical regimes of worth and not privilege excellence. Here
the principle investigator provided an optimistic vision of being able to
transfer from one predominant regime of worth to another, anticipated
(though not yet as durable) regime of worth. Although he appeared confi-
dent in being able to muddle through these different regimes, his account
points to an “ontological gap” between an excellence regime consolidated
through calculative infrastructures, on the one hand, and more promissory,
relatively ephemeral values and ambiguous forms of worth associated with
patient relevance, on the other.
Discussion
In recent years, STS inquiries into the practical work of academic research
have become increasingly interested in how growth of research
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governance—including intensified monitoring and evaluation of perfor-
mance—is impacting research and academic life in universities more
generally.
While policy makers and other actors may privilege particular regimes
of worth in their measurement of performance (often at the expense of or
in combination with others), we have refocused the need to open up how
researchers—an obligatory passage point for research policy—strategi-
cally engage in their own kinds practices of accumulating worth. Drawing
on emerging research in the sociology of (e)valuation, we contend that
there is no singularity to (e)valuation in academia, but rather a multiplicity
of (e)valuative practices and infrastructures. This in our view provokes an
interesting new avenue of investigation for STS, namely, how are con-
temporary research practices being configured around multiple, hierarchi-
cally ordered regimes of worth? Through retrieving and updating classic
STS accounts of research as a capitalist-style process of accumulating
worth of various sorts, recent conceptual developments on epistemic
capitalism provide a series of helpful insights for approaching this puzzle.
In this scheme, the capitalistic or entrepreneurial accumulation of worth is
not a voluntaristic property of individuals and groups. Rather, it emerges
as a set of contingent outcomes of organizational and infrastructural rela-
tions. As such, some forms of worth become more durable and powerful
(“capital”) by virtue of being embedded in standardized infrastructures
like citation measurements.
Building on these insights, we explored how principal investigators of
two biomedical research groups in a Dutch academic medical center navi-
gated and exploited multiple regimes of worth through building portfolios
of basic and clinical inquiries within their groups. Our analysis examined
how portfolio construction emerged around groups’ research technology
ensembles, which both enabled and constrained opportunities either to steer
research activities toward novel areas of inquiry or expand into existing
ones considered promising vis-à-vis the excellence and/or patient relevance
regimes of worth. Based on our findings, we suggest the following insights
about the portfolio might be instructive for future STS research on episte-
mic capitalism.
First, the concept of portfolio can be useful for exploring researchers’
efforts to satisfy coexisting regimes of worth that appear to be in friction
with one another. Relating to the notion of heterarchy (Stark 2009), the
portfolio helped us make sense of how biomedical principle investigators
sought to align their spheres of inquiry in relation to both the excellence and
patient-relevant regimes of worth (a dichotomy widely embedded across
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contemporary biomedical research). For example, in our second case, the
human genetics principal investigator used his research technology ensem-
ble to scale a clinical sphere of inquiry, thereby initiating a transition from
work framed as relevant to a hitherto dominant regime of worth (excel-
lence) toward work relevant to a prospective regime (patient relevance). In
the short term, however, a combined basic and clinical portfolio enabled
him to keep both regimes of worth in play. Comparative studies situating
“portfolio management” practices in relatively pluralistic versus hierarch-
ical evaluative situations would help further crystallize the scope of the
portfolio as a concept for theorizing research problem construction, identity
work, and risk management practices in contemporary academic research
groups.
Second, accounts of the performative effects of evaluation on academic
research practices often suggest that dominant regimes of worth risk over-
riding the ability to conduct research that is not supported by durable
regimes of worth. While this is surely an important concern, our empirical
account of portfolio strategies showed how riskier problems underpinned by
less stable forms of worth were kept in play by combining them with more
“mainstream” problems underpinned by relatively stable measures of
worth. Returning to the vocabulary of financial capitalism, portfolio invest-
ment may help to “spread risk” and support “niche” areas of inquiry, there-
fore mitigating—at least partially—potential pressures to conform to
dominant, perhaps conservative, hierarchies of worth. In line with Birch’s
(2017, 439) recent call for STS scholars to examine technoeconomic
assumptions underpinning contemporary forms of research organization
and governance, we suggest that notions like “investment alternatives,”
“risk management,” and “return on investment” offer a promising set of
concepts to tinker with in exploring epistemic capitalist practices of port-
folio construction.
Third, portfolio strategies are not only about reacting to emerging
regimes of worth; they can also support scaling existing spheres of inquiry
in order to latch onto already well-established regimes of worth. For exam-
ple, the immunology group leader in our first case felt optimistic about
opening a new line of inquiry—from an already established research tech-
nology ensemble—with which her group might continue to target high-
impact factor journals. As such, although portfolio strategies can be useful
in making sense of situations where multiple regimes of worth are consid-
ered important, it would also be a useful means of accounting for how group
leaders seek to latch onto dominant hierarchical regimes of worth by
“investing” in different research problems within the group.
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Fourth, studies focusing on the changing subjectivities of academic
researchers in relation to emerging “capitalist” accumulation practices may
wish to explore further how notions of self-worth become attached to
portfolio-building practices for exploiting multiplicity. Promising research
questions include to what extent are portfolio practices constitutive of new
(academic) entrepreneurial selves? to whom is this new normal (not) avail-
able? and what forms of academic (self)worth are displaced, damaged, or
excluded from such practices? Furthermore, whether portfolio strategies
manifest similarly in epistemic domains other than biomedicine—for exam-
ple, those that utilize “research systems” (Hackett et al. 2004) less amenable
toward processes of “rapid discovery science” (Collins 1994)—is an impor-
tant empirical question our paper raises for future theorizing on portfolios.
For instance, portfolio strategies in social science and humanities might
crucially include “teaching,” both as an activity and as a regime of worth,
that plays an important role in sustaining research activities in disciplines
where resources are generally scarce.
Finally, our account of portfolios serves as a reminder that (e)valuative
infrastructures are dynamic. This means their durability and importance can
change over time, and, perhaps more importantly, can be changed. How-
ever, our account suggests that changes are most likely to be rather slow and
indeterminate: the ability of academic medical centers to establish heter-
archical modes of worth in which patient-relevant research can be capita-
lized upon sufficiently to sustain research groups is likely to prove a wicked
problem going forward.
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1. Lamont (2009, 2012) has also argued that in an era of new public management–
inspired research governance, peer review—long a touchstone in judging quality
among colleagues in academic communities—has increasingly been enrolled as a
technology to monitor and evaluate academic performance and promote
excellence.
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